Ridgefield, Connecticut, home to our U.S. headquarters, is ranked #1 safest place to live
Read about what makes Ridgefield, Connecticut a great place to live, work, and make a difference in the lives of people and animals.
Search
Skin and Inflammatory Diseases
skin diseases
Hannah Bussmann
Get an inside view of life at Boehringer Ingelheim with Hannah Bussmann.
Partnering in CardioMetabolic Diseases
Partnering in CardioMetabolic Diseases
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.
Biosimilars
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Explore our company
Make your next career step at Boehringer Ingelheim. Explore our various fields to find out more about employment opportunities in your area of interest.
More Potential
More Potential
Oncology & Cancer Immunology
Oncology & Cancer Immunology
Our Partners: ViraTherapeutics
Our Partners: ViraTherapeutics
Leticia develops product medical strategies
Leticia develops product medical strategies at Boehringer Ingelheim. For more talent insights, visit our Careers Page.
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Dr. Wolchinsky Receives Pioneer Award | Boehringer Ingelheim US
Read more about Dr. Steven Wolchinsky receiving the first Vetmedin® (pimobendan) Cardiology Pioneer award, for his work and commitment to animal health.
Office Hours Program | Partnering
Click here to find out how Boehringer Ingelheim's pioneering ‘Office Hours’ program has now mentored over 250 early-stage companies since 2015.
Scleroderma
Scleroderma
Our Responsibility
Our Responsibility
Meet our Team
Meet Our Team
Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease
Sustainable Development - Our Commitment
Our Commitment
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Therapeutics
Therapeutics
From the archives: Maria Plum’s story as a pioneer of her time
Maria Plum was one of the first female lawyers in Germany, and she served as legal counselor for our company starting in the 1930s. Read account of her story written by Katrin Lege, Head of the Boehringer Ingelheim Company Archives, who discovered details
Patient Centricity
Patient Centricity
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach